IQVIA’s (IQV) Equal Weight Rating Reaffirmed at Barclays

Barclays reissued their equal weight rating on shares of IQVIA (NYSE:IQV) in a research note released on Thursday morning, Marketbeat reports. The brokerage currently has a $170.00 target price on the medical research company’s stock, down from their prior target price of $235.00.

Several other research analysts have also recently commented on IQV. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Mizuho cut their target price on IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a research report on Wednesday. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Truist Financial dropped their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research report on Thursday. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

IQVIA Price Performance

Shares of NYSE IQV opened at $142.96 on Thursday. The firm has a market cap of $25.21 billion, a P/E ratio of 19.06, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The business’s 50 day moving average is $183.41 and its 200-day moving average is $200.24. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a 1-year low of $135.97 and a 1-year high of $252.88.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts predict that IQVIA will post 10.84 earnings per share for the current year.

Institutional Trading of IQVIA

Institutional investors have recently modified their holdings of the business. American National Bank & Trust acquired a new position in IQVIA during the 1st quarter worth about $26,000. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter worth about $33,000. ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in IQVIA during the 4th quarter valued at approximately $39,000. Finally, Lee Danner & Bass Inc. bought a new position in IQVIA during the 4th quarter worth approximately $44,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.